AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk

RecruitingNAAges 18 Years - anyAllInstitut Cancerologie de l'Ouest
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Coagulation is a complex system which, through the action of thrombin, leads to the formation of fibrin, which stabilises the platelet clot. Any disturbance in the balance between procoagulant and anticoagulant factors can tip the physiological process either towards a state of hypercoagulability leading to thrombosis or hypocoagulability responsible for bleeding. Due to a number of factors, cancer is associated with a state of hypercoagulability, leading to thrombosis. The incidence of venous thromboembolism (VTE) in cancer patients varies from 15 to 20% depending on the type of cancer, the stage of the disease and the associated treatments (ONCORIF data, November 2021). The risk of venous thromboembolism (VTE) is greatly increased in cancer patients (RR x 3 to 6) and doubled in the case of associated chemotherapy (1). VTE is a poor prognostic factor, occurs mainly in the first 6 month

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Patient aged \> 18 years, 2. Patient with a solid cancer at high risk of thrombosis, whether metastatic or not (lung, pancreatic, gastric or glioblastoma cancers)1, 3. Patients who have not received any systemic treatment for their cancer, 4. An informed patient who does not object to the use of data for research purposes and who has consented to the collection, use and storage of biological samples. Exclusion Criteria: 1. Patient who has had a VTE in the 12 months preceding the diagnosis of cancer, 2. Patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin K2, 3. Women who are pregnant, likely to become pregnant or who are breast-feeding, 4. Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian, 5. Unable to undergo medical monitoring of the trial for geographical, social or psychological reasons.
๐Ÿ’Š

What it tests

  • thrombogram
๐Ÿ“

Where

1 site
Institut de Cancerologie de L'Ouest
Saint-Herblain, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy